Evaxion’s AI Technology Identifies Targets for Cancer Vaccines in Latest News

Danish biotech company Evaxion Biotech has shared positive clinical results from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma. Conducted in collaboration with several institutions including DTU and Rigshospitalet, the trial demonstrated that Evaxion’s AI-powered PIONEER platform is able to identify high-quality cancer vaccine targets, termed neoantigens, associated with longer progression-free survival. Of the 12 patients treated with EVX-01, eight (67%) demonstrated positive clinical responses, with strong neoantigen T-cell responses observed in all patients alongside the induction of vaccine-specific immune responses in all cases. Higher doses of the vaccine produced a stronger immune response, which was associated with an improved clinical outcome. The results from the Phase 1 trial position Evaxion to prospectively identify patients who might benefit from personalized cancer immunotherapy in coming trials.